ArticleClinical journal of gastroenterology2025
Immune-related adverse events in patients with low baseline serum IL-6 treated with durvalumab plus tremelimumab for hepatocellular carcinoma: a case series.
Tsubasa Nobusawa et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.